Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity upon House Dust Mite Skin Challenge in Patients Suffering from Moderate to Severe Atopic Dermatitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs ANB 020 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacodynamics; Proof of concept
- Sponsors AnaptysBio
- 10 Oct 2017 Top-line results presented in an AnaptysBio media release.
- 10 Oct 2017 According to an AnaptysBio media release, Dr. Graham Ogg, professor of dermatology at University of Oxford, is the principal investigator of this trial. The company plans to report full data from this trial at a medical conference following study completion.
- 10 Aug 2017 Status changed from recruiting to active, no longer recruiting, according to an AnaptysBio media release.